MAB DESIGNS LIMITED
MAB Designs is a London-based, privately held biotech founded in 2011 that develops antibody-based therapeutics using selective IL-6 trans-signaling inhibition technology, operating with a small team of 1-10 employees.
- Company typePrivate
- Founded2011
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What MAB DESIGNS LIMITED does
MAB DESIGNS LIMITED is a privately held, London-based biotechnology company founded in 2011 that develops antibody-based therapeutics centered on selective IL-6 trans-signaling inhibition. IL-6 trans-signaling is a specific branch of the IL-6 cytokine pathway implicated in chronic inflammation, autoimmune disease, and certain oncology indications; selective inhibition of this pathway (as opposed to blocking all IL-6 signaling) is the company's stated technical differentiator and forms the basis of its therapeutic platform. The company operates with a very small team of 1-10 employees, consistent with an early-stage or pre-clinical biotech operating model.
No commercial revenue, funding rounds, licensing deals, partnerships, clinical milestones, or named management team are disclosed in the available source material. The firm's website (mabdesigns.co.uk) is the only public-facing asset referenced, and the captured page content consists solely of a loading/verification screen rather than substantive product, pipeline, or investor information. There is no indication of active capital formation, M&A activity, regulatory filings, or product launches within the source data set. As a result, the company's current operating posture, capital structure, and pipeline stage cannot be verified beyond the founding information and stated therapeutic focus.
MAB DESIGNS LIMITED firmographics
Firmographics- Name
- MAB DESIGNS LIMITED
- Legal name
- MAB DESIGNS LIMITED
- Website
- https://mabdesigns.co.uk
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 1–10 employees
- Short description
- MAB Designs is a London-based, privately held biotech founded in 2011 that develops antibody-based therapeutics using selective IL-6 trans-signaling inhibition technology, operating with a small team of 1-10 employees.
- Ownership category
- akta.pro rank
MAB DESIGNS LIMITED industry classification
Industry- Product category
- Biopharmaceutical Antibody Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where MAB DESIGNS LIMITED is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
MAB DESIGNS LIMITED business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
MAB DESIGNS LIMITED product offering
Product offeringCore offering
MAB Designs develops antibody-based therapeutics built on selective IL-6 trans-signaling inhibition technology. The company targets IL-6-driven inflammatory and immune-mediated disease biology by blocking the disease-associated signal-transducing complex while sparing classical IL-6 signaling. Its offering centers on proprietary monoclonal antibody R&D aimed at chronic inflammation and autoimmune indications.
Differentiator
Problem solved
Functional benefit
Products and services
- Selective IL-6 Trans-Signaling Antibody Program An antibody-based therapeutic program targeting selective inhibition of IL-6 trans-signaling for the treatment of inflammatory and immune-mediated diseases. Intended for pharmaceutical partners developing treatments for chronic inflammatory and autoimmune indications.
MAB DESIGNS LIMITED technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MAB DESIGNS LIMITED partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights2 records
MAB DESIGNS LIMITED competitors and assessment
Company assessmentBroad incumbents
- argenx: argenx is a commercial-stage antibody therapeutics company developing Fc-engineered and ligand-blocking antibodies for autoimmune and inflammatory diseases; it is comparable as an established antibody-engineering platform player in the same therapeutic space.
- AbCellera Biologics: AbCellera is an antibody discovery and engineering platform that partners with pharma to generate therapeutic antibodies, including in immunology; it is comparable as a broader antibody-engineering counterpart that could partner with or compete against MAB Designs' discovery capabilities.
- IFM Therapeutics (acquired by BMS): IFM Therapeutics developed NLRP3 and cGAS inhibitors for inflammation and was acquired by Bristol-Myers Squibb; it is comparable as a small-molecule inflammation company that operated as a target-discovery platform in the same inflammatory disease space, illustrating the typical acquisition trajectory for a niche inflammation player.
Regional players
- Vivantes Pharma: Vivantes Pharma is a European-focused developer of IL-6 / inflammation-related antibody therapeutics; it is comparable as a regional IL-6-pathway antibody competitor in the same geographic and mechanistic space.
Direct peers
- Roche: Roche markets tocilizumab (Actemra), the leading IL-6R-inhibiting antibody used in inflammatory and autoimmune diseases; it is the most directly comparable commercial benchmark for a company developing IL-6-pathway antibody therapeutics.
- Janssen / Johnson & Johnson (siltuximab): Janssen markets siltuximab (Sylvant), an anti-IL-6 monoclonal antibody approved for multicentric Castleman's disease, making it a direct competitor in IL-6-targeting antibody therapeutics.
- Sanofi (with Regeneron): Sanofi and Regeneron co-developed sarilumab (Kevzara), an IL-6R antibody approved for rheumatoid arthritis; this is a direct competitor in the IL-6/IL-6R antibody space and a likely acquirer or licensor of next-generation IL-6 modulators.
Emerging players
- R-Pharm / UCB (olokizumab): Olokizumab is a direct anti-IL-6 monoclonal antibody developed by R-Pharm and partnered with UCB; it is a direct IL-6-pathway antibody competitor advancing through late-stage clinical development.
- SynAct Pharma: SynAct Pharma is developing AP1189, a biased melanocortin receptor agonist that selectively inhibits IL-6 trans-signaling-driven inflammation; it is one of the closest small-cap mechanistic competitors to MAB Designs' selective IL-6 trans-signaling approach.
- Boston Pharma: Boston Pharma is a clinical-stage biopharmaceutical company developing therapies for inflammatory and metabolic diseases, including cytokine-modulating candidates; it is a comparable emerging inflammation therapeutics competitor.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
MAB DESIGNS LIMITED social profiles
Digital presenceMAB DESIGNS LIMITED financial estimates
Financial estimateRevenue estimate
Valuation estimate
MAB DESIGNS LIMITED leadership team
Management profileNumber of profiles
MAB DESIGNS LIMITED funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MAB DESIGNS LIMITED M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MAB DESIGNS LIMITED
What does MAB DESIGNS LIMITED do?
MAB Designs develops antibody-based therapeutics built on selective IL-6 trans-signaling inhibition technology. The company targets IL-6-driven inflammatory and immune-mediated disease biology by blocking the disease-associated signal-transducing complex while sparing classical IL-6 signaling. Its offering centers on proprietary monoclonal antibody R&D aimed at chronic inflammation and autoimmune indications.
When was MAB DESIGNS LIMITED founded?
MAB DESIGNS LIMITED was founded in 2011. It employs 1 to 10 people.
Where is MAB DESIGNS LIMITED based?
MAB DESIGNS LIMITED is headquartered in London, United Kingdom, in the Europe region.
Who are MAB DESIGNS LIMITED's main competitors?
Broad incumbents on record are argenx, AbCellera Biologics and IFM Therapeutics (acquired by BMS). Vivantes Pharma is listed as a regional player. Direct peers are Roche, Janssen / Johnson & Johnson (siltuximab) and Sanofi (with Regeneron). Emerging players are R-Pharm / UCB (olokizumab), SynAct Pharma and Boston Pharma.
Does MAB DESIGNS LIMITED have an API?
No public API is recorded for MAB DESIGNS LIMITED.
What industry is MAB DESIGNS LIMITED in?
MAB DESIGNS LIMITED's product category is Biopharmaceutical Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.